Challenging the roles of CD44 and lipolysis stimulated lipoprotein receptor in conveying Clostridium perfringens iota toxin cytotoxicity in breast cancer

[1]  M. Popoff,et al.  Challenging the roles of CD44 and lipolysis stimulated lipoprotein receptor in conveying Clostridium perfringens iota toxin cytotoxicity in breast cancer , 2014, Molecular Cancer.

[2]  David W. Scott,et al.  The Role of Lipolysis Stimulated Lipoprotein Receptor in Breast Cancer and Directing Breast Cancer Cell Behavior , 2014, PloS one.

[3]  M. Kurosumi,et al.  Androgen metabolite-dependent growth of hormone receptor-positive breast cancer as a possible aromatase inhibitor-resistance mechanism , 2013, Breast Cancer Research and Treatment.

[4]  Syreeta L. Tilghman,et al.  Proteomic Signatures of Acquired Letrozole Resistance in Breast Cancer: Suppressed Estrogen Signaling and Increased Cell Motility and Invasiveness* , 2013, Molecular & Cellular Proteomics.

[5]  M. Furuse,et al.  Analysis of the ‘angulin’ proteins LSR, ILDR1 and ILDR2 – tricellulin recruitment, epithelial barrier function and implication in deafness pathogenesis , 2013, Journal of Cell Science.

[6]  B. McClane,et al.  Human Claudin-8 and -14 Are Receptors Capable of Conveying the Cytotoxic Effects of Clostridium perfringens Enterotoxin , 2013, mBio.

[7]  T. Veenstra,et al.  CD44 Promotes Intoxication by the Clostridial Iota-Family Toxins , 2012, PloS one.

[8]  J. Rodriguez-Canales,et al.  Characterization of Δ7/11, a functional prolactin-binding protein. , 2012, Journal of molecular endocrinology.

[9]  H. Ditzel,et al.  Functional Heterogeneity within the CD44 High Human Breast Cancer Stem Cell-Like Compartment Reveals a Gene Signature Predictive of Distant Metastasis , 2012, Molecular medicine.

[10]  Cynthie Wong,et al.  The development, application and limitations of breast cancer cell lines to study tamoxifen and aromatase inhibitor resistance , 2012, The Journal of Steroid Biochemistry and Molecular Biology.

[11]  D. Tiezzi,et al.  CD44+/CD24− cells and lymph node metastasis in stage I and II invasive ductal carcinoma of the breast , 2012, Medical Oncology.

[12]  B. Pockaj,et al.  Human Breast Cancer Stem Cells Have Significantly Higher Rate of Clathrin-Independent and Caveolin-Independent Endocytosis than the Differentiated Breast Cancer Cells. , 2012, Journal of cancer science & therapy.

[13]  R. Tashiro,et al.  Intracellular Trafficking of Clostridium perfringens Iota-Toxin b , 2012, Infection and Immunity.

[14]  I. Fichtner,et al.  Novel Clostridium perfringens enterotoxin suicide gene therapy for selective treatment of claudin-3- and -4-overexpressing tumors , 2011, Gene Therapy.

[15]  M. Ringnér,et al.  CD44 isoforms are heterogeneously expressed in breast cancer and correlate with tumor subtypes and cancer stem cell markers , 2011, BMC Cancer.

[16]  G. Bell,et al.  Lipolysis-stimulated lipoprotein receptor (LSR) is the host receptor for the binary toxin Clostridium difficile transferase (CDT) , 2011, Proceedings of the National Academy of Sciences.

[17]  A. Giatromanolaki,et al.  The CD44+/CD24− phenotype relates to ‘triple-negative’ state and unfavorable prognosis in breast cancer patients , 2011, Medical oncology.

[18]  André F. Vieira,et al.  Breast cancer stem cell markers CD44, CD24 and ALDH1: expression distribution within intrinsic molecular subtype , 2011, Journal of Clinical Pathology.

[19]  M. Zöller.  CD44: can a cancer-initiating cell profit from an abundantly expressed molecule? , 2011, Nature Reviews Cancer.

[20]  Charles M Perou,et al.  Systems biology and genomics of breast cancer. , 2011, Cold Spring Harbor perspectives in biology.

[21]  L. Johannes,et al.  Endocytosis and toxicity of clostridial binary toxins depend on a clathrin‐independent pathway regulated by Rho‐GDI , 2011, Cellular microbiology.

[22]  Louis W. Chang,et al.  Pharmacokinetics and physiologically-based pharmacokinetic modeling of nanoparticles. , 2010, Journal of nanoscience and nanotechnology.

[23]  C. Svendsen,et al.  Gene therapy-mediated delivery of targeted cytotoxins for glioma therapeutics , 2010, Proceedings of the National Academy of Sciences.

[24]  Jason I. Herschkowitz,et al.  Phenotypic and molecular characterization of the claudin-low intrinsic subtype of breast cancer , 2010, Breast Cancer Research.

[25]  Charles M Perou,et al.  Clinical implementation of the intrinsic subtypes of breast cancer. , 2010, The Lancet. Oncology.

[26]  C. Maxwell,et al.  Targeting tumour-initiating cells to improve the cure rates for triple-negative breast cancer , 2010, Expert Reviews in Molecular Medicine.

[27]  B. Vonderhaar,et al.  CD44posCD49fhiCD133/2hi defines xenograft-initiating cells in estrogen receptor-negative breast cancer. , 2010, Cancer research.

[28]  H. Barth,et al.  The Long-Lived Nature of Clostridium perfringens Iota Toxin in Mammalian Cells Induces Delayed Apoptosis , 2009, Infection and Immunity.

[29]  Robert L. Sutherland,et al.  Biological determinants of endocrine resistance in breast cancer , 2009, Nature Reviews Cancer.

[30]  I. Pastan,et al.  Phase I Trial of Continuous Infusion Anti-Mesothelin Recombinant Immunotoxin SS1P , 2009, Clinical Cancer Research.

[31]  C. MacKintosh,et al.  Differential 14-3-3 Affinity Capture Reveals New Downstream Targets of Phosphatidylinositol 3-Kinase Signaling* , 2009, Molecular & Cellular Proteomics.

[32]  I. Ellis,et al.  Triple-Negative Breast Cancer: Distinguishing between Basal and Nonbasal Subtypes , 2009, Clinical Cancer Research.

[33]  Anne-Mette K. Hein,et al.  Increased cell motility and invasion upon knockdown of lipolysis stimulated lipoprotein receptor (LSR) in SW780 bladder cancer cells , 2008, BMC Medical Genomics.

[34]  Hongbo Zhao,et al.  N‐Glycosylation affects the adhesive function of E‐Cadherin through modifying the composition of adherens junctions (AJs) in human breast carcinoma cell line MDA‐MB‐435 , 2008, Journal of cellular biochemistry.

[35]  Samuel Leung,et al.  Basal-Like Breast Cancer Defined by Five Biomarkers Has Superior Prognostic Value than Triple-Negative Phenotype , 2008, Clinical Cancer Research.

[36]  H. Barth,et al.  Binary actin-ADP-ribosylating toxins and their use as molecular Trojan horses for drug delivery into eukaryotic cells. , 2008, Current medicinal chemistry.

[37]  C. Perou,et al.  The Triple Negative Paradox: Primary Tumor Chemosensitivity of Breast Cancer Subtypes , 2007, Clinical Cancer Research.

[38]  M. Rossing,et al.  Hormone receptor status, tumor characteristics, and prognosis: a prospective cohort of breast cancer patients , 2007, Breast Cancer Research.

[39]  I. Pastan,et al.  Immunotoxin treatment of cancer. , 2007, Annual review of medicine.

[40]  W. Knudson,et al.  Acylation of CD44 and Its Association with Lipid Rafts Are Required for Receptor and Hyaluronan Endocytosis* , 2006, Journal of Biological Chemistry.

[41]  M. Kukuruzinska,et al.  N-Glycosylation Affects the Molecular Organization and Stability of E-cadherin Junctions* , 2006, Journal of Biological Chemistry.

[42]  L. O’Driscoll,et al.  Biomarkers and multiple drug resistance in breast cancer. , 2006, Current cancer drug targets.

[43]  Roman Rouzier,et al.  Nomograms to predict pathologic complete response and metastasis-free survival after preoperative chemotherapy for breast cancer. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[44]  Sebastian Harder,et al.  Phase I clinical study of the recombinant antibody toxin scFv(FRP5)-ETA specific for the ErbB2/HER2 receptor in patients with advanced solid malignomas , 2005, Breast Cancer Research.

[45]  Y Wang,et al.  Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials , 2005, The Lancet.

[46]  P. Michl,et al.  Bacteria and bacterial toxins as therapeutic agents for solid tumors. , 2004, Current cancer drug targets.

[47]  P. Brown,et al.  The origins of estrogen receptor alpha-positive and estrogen receptor alpha-negative human breast cancer , 2004, Breast Cancer Research.

[48]  B. Groner,et al.  Regression of Cutaneous Tumor Lesions in Patients Intratumorally Injected with a Recombinant Single-chain Antibody-toxin Targeted to ErbB2/HER2 , 2003, Breast Cancer Research and Treatment.

[49]  Minetta C. Liu,et al.  Antiestrogen resistance in breast cancer and the role of estrogen receptor signaling , 2003, Oncogene.

[50]  R. Puri,et al.  Interleukin-13 Receptor-Directed Cytotoxin for Malignant Glioma Therapy: From Bench to Bedside , 2003, Journal of Neuro-Oncology.

[51]  E. Ko,et al.  Regression of prostate cancer xenografts by a lentiviral vector specifically expressing diphtheria toxin A , 2003, Cancer Gene Therapy.

[52]  R. Tibshirani,et al.  Repeated observation of breast tumor subtypes in independent gene expression data sets , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[53]  A. Hochberg,et al.  Inhibition of tumor growth by DT-A expressed under the control of IGF2 P3 and P4 promoter sequences. , 2003, Molecular therapy : the journal of the American Society of Gene Therapy.

[54]  E. J. Lee,et al.  Cell-specific Cre-mediated activation of the diphtheria toxin gene in pituitary tumor cells: potential for cytotoxic gene therapy. , 2002, Human gene therapy.

[55]  G. Mainguy,et al.  Transcytosis of iota‐toxin across polarized CaCo‐2 cells , 2002, Molecular microbiology.

[56]  R. Tibshirani,et al.  Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[57]  M. Pfaffl,et al.  A new mathematical model for relative quantification in real-time RT-PCR. , 2001, Nucleic acids research.

[58]  Leonard A. Smith,et al.  Clostridium perfringens Iota-Toxin: Mapping of Receptor Binding and Ia Docking Domains on Ib , 2001, Infection and Immunity.

[59]  L. Bougueleret,et al.  Molecular Cloning of a Lipolysis-stimulated Remnant Receptor Expressed in the Liver* , 1999, The Journal of Biological Chemistry.

[60]  I. Stamenkovic,et al.  Glycosylation Provides Both Stimulatory and Inhibitory Effects on Cell Surface and Soluble CD44 Binding to Hyaluronan , 1998, The Journal of cell biology.

[61]  E. Oldfield,et al.  Tumor regression with regional distribution of the targeted toxin TF-CRM107 in patients with malignant brain tumors , 1997, Nature Medicine.

[62]  J. Songer.  Clostridial enteric diseases of domestic animals , 1996, Clinical microbiology reviews.

[63]  I. Stamenkovic,et al.  Glycosylation of CD44 is implicated in CD44-mediated cell adhesion to hyaluronan , 1996, The Journal of cell biology.

[64]  K. Bennett,et al.  Regulation of CD44 binding to hyaluronan by glycosylation of variably spliced exons , 1995, The Journal of cell biology.

[65]  C. Mann,et al.  Mechanism of activation and functional significance of the lipolysis-stimulated receptor. Evidence for a role as chylomicron remnant receptor. , 1995, Biochemistry.

[66]  J. Sakùrai,et al.  Lethal and Dermonecrotic Activities of Clostridium perfringens Iota Toxin: Biological Activities Induced by Cooperation of Two Nonlinked Components , 1995, Microbiology and immunology.

[67]  J. Sleeman,et al.  CD44 isoforms in metastatic cancer. , 1994, Invasion & metastasis.

[68]  V. Bordeau,et al.  Identification of a lipolysis-stimulated receptor that is distinct from the LDL receptor and the LDL receptor-related protein. , 1994, Biochemistry.

[69]  C. Osborne,et al.  Tamoxifen resistance in breast cancer. , 1993, Critical reviews in oncology/hematology.

[70]  J. Vandekerckhove,et al.  Clostridium perfringens iota toxin ADP‐ribosylates skeletal muscle actin in Arg‐177 , 1987, FEBS letters.

[71]  T. Wilkins,et al.  Molecular basis for the pathological actions of Clostridium perfringens iota toxin , 1987, Infection and immunity.

[72]  P. Herrlich,et al.  CD44: From adhesion molecules to signalling regulators , 2003, Nature Reviews Molecular Cell Biology.

[73]  M. Mock,et al.  Immunological and functional comparison between Clostridium perfringens iota toxin, C. spiroforme toxin, and anthrax toxins. , 1997, FEMS microbiology letters.

[74]  M. Schwartz.  Institut Pasteur , 1895, Science.